The definition of refractoriness to platelet transfusions
- PMID: 1308461
- DOI: 10.1111/j.1365-3148.1992.tb00132.x
The definition of refractoriness to platelet transfusions
Abstract
The relationship between the 1 and 20 h post-transfusion platelet count and three parameters used to define refractory transfusions, namely the corrected increment (CI), platelet increment (PI), and percentage platelet recovery (%REC), was studied in 437 non-HLA matched platelet transfusions given to 102 patients with bone marrow failure. The percentage agreement between common definitions of refractoriness was calculated based on these parameters. As the maintenance of platelet counts above 20 x 10(9)/l is a relevant clinical goal for platelet support, the values of the CI, PI and %REC, which best corresponded to 1- and 20-h post-transfusion counts of 20 x 10(9)/l, were identified. A 1-h post-transfusion CI < 3 (PI < 7 x 10(9)/l or % REC < 8%) corresponded to clinically unsuccessful transfusions with a 1-h platelet count < 20 x 10(9)/l. A 1-h CI > or = 5.5 (PI > or = 12 x 10(9)/l or %REC > or = 14%) corresponded to clinically successful transfusions with a 20-h post-transfusion count of > or = 20 x 10/l. These data tie together the end points reported in the literature for defining refractory transfusions.
Comment in
-
Formulae for the definition of refractoriness to platelet transfusion.Transfus Med. 1993 Mar;3(1):91-3. doi: 10.1111/j.1365-3148.1993.tb00108.x. Transfus Med. 1993. PMID: 8038900 No abstract available.
Similar articles
-
Clinical perspectives of platelet transfusions: defining the optimal dose.J Clin Apher. 1995;10(3):124-7. doi: 10.1002/jca.2920100305. J Clin Apher. 1995. PMID: 8582893
-
Determination in vivo viability of a transfused platelet product by corrected count increment and percentage platelet response.Pan Afr Med J. 2017 Jul 28;27:226. doi: 10.11604/pamj.2017.27.226.12116. eCollection 2017. Pan Afr Med J. 2017. PMID: 28979628 Free PMC article.
-
The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding.Semin Oncol. 1993 Oct;20(5 Suppl 6):102-9. Semin Oncol. 1993. PMID: 8211211 Review.
-
Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.Transfus Med Rev. 2020 Oct;34(4):250-257. doi: 10.1016/j.tmrv.2020.09.010. Epub 2020 Oct 7. Transfus Med Rev. 2020. PMID: 33127210 Review.
-
Complement as an Immune Barrier in Platelet Transfusion Refractoriness.Transfus Med Rev. 2019 Oct;33(4):231-235. doi: 10.1016/j.tmrv.2019.09.003. Epub 2019 Oct 18. Transfus Med Rev. 2019. PMID: 31679761 Review.
Cited by
-
Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis.Front Med (Lausanne). 2022 May 6;9:873500. doi: 10.3389/fmed.2022.873500. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35602482 Free PMC article.
-
Platelet transfusion refractoriness: how do I diagnose and manage?Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):527-532. doi: 10.1182/hematology.2020000137. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275694 Free PMC article. Review.
-
Applicability of an instrument to identify human leukocyte antigen-compatible donors for platelet transfusions.Hematol Transfus Cell Ther. 2018 Oct-Dec;40(4):298-304. doi: 10.1016/j.htct.2018.03.004. Epub 2018 May 22. Hematol Transfus Cell Ther. 2018. PMID: 30370406 Free PMC article.
-
Quality assessment and transfusion efficacy of buffy coat-derived platelet concentrates washed with platelet additive solution.Blood Transfus. 2018 May;16(3):273-278. doi: 10.2450/2017.0277-16. Epub 2017 Apr 13. Blood Transfus. 2018. PMID: 28488971 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
